Probiotic Blend of Lactobacillus acidophilus LA‐5 and Bifidobacterium animalis ssp. Lactis BB‐12 in Non‐constipated Irritable Bowel Syndrome: A Double‐Blind Randomized Placebo‐Controlled Trial
Journal of Gastroenterology and Hepatology · 2026
DOI: 10.1111/jgh.70137 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Uday C Ghoshal und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. Hauptthemen laut MEDLINE: Probiotics, Irritable Bowel Syndrome, Lactobacillus acidophilus, Bifidobacterium animalis. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Zydus Healthcare Limited and Shanti Public Educational and Development Society.
Abstract (Originalsprache)
Background
As dysregulated gut microbiota is known in irritable bowel syndrome (IBS) and probiotics may improve it, we investigated the efficacy and safety of a combination probiotic, Lactobacillus acidophilus LA‐5 and Bifidobacterium animalis ssp. lactis BB‐12 in non‐constipated IBS.
Methods
Two hundred non‐constipated IBS patients were randomized to the above‐mentioned probiotic and placebo for 84 days. The outcome measures included IBS–Global Improvement Scale (IBS‐GIS), IBS–Quality of Life (IBS‐QoL), EAR3Q, IBS–Severity Scoring System (IBS‐SSS), and patient‐reported improvement. Fecal microbiota was evaluated in a subset.
Results
Response in IBS‐GIS was higher with probiotics than with placebo at days 28 (19.3% vs. 8.9%; p = 0.048), 56, and 84. Total and abdominal pain, distension, and QoL scores of IBS‐SSS decreased at day 28 with probiotics that persisted till days 56 and 84. The percentage of patients with “severe” symptoms reduced from 20.8% at baseline to 3.9% at day 84, and the median IBS‐QoL score decreased significantly at day 28; the beneficial effect on QoL was sustained till days 56 and 84 ( p < 0.001). Improvement in abdominal pain, distension, urgency of defecation, bowel habit satisfaction, and stool frequency was noted earlier with probiotics than with placebo; 4.0% in the probiotic group and 0.9% in the placebo group had mild/moderate adverse events ( p = 0.167). Symptom recurrence occurred in 3.0% in the probiotic group and 3.9% in the placebo group during follow‐up of 180 days ( p = 0.718). No difference was observed in the fecal microbiota between the two groups, but healthy genera were enriched with probiotics.
Conclusions
The probiotic blend studied was more effective than placebo in non‐constipated IBS in adults.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
- Institute of Gastrosciences & Liver Transplantation, Apollo Multispeciality Hospitals, Kolkata, India.
- Department of Gastroenterology, SRM Institutes of Medical Sciences (SIMS Hospital), Chennai, India.
- Department of Gastroenterology, Topiwala National Medical College & BYL Nair Charitable Hospital, Mumbai, India.
- Department of Gastroenterology, Seth G S Medical College and KEM Hospital, Mumbai, India.
- Department of Gastroenterology, All India Institute of Medical Science, Bhubaneswar, India.
ORCID-Profile: Uday C Ghoshal, Akash Shukla, Shubham Jain, Sanjay Chandnani, Mahesh K Goenka
Förderung
- Zydus Healthcare Limited and Shanti Public Educational and Development Society
Zitieren
APA
Ghoshal, U. C., Ramakrishna, B. S., Rathi, P. M., Shukla, A., Panigrahi, M. K., Jain, S., Saha, I., Chakravartty, K., Singh, M., Mustafa, U., Sahu, S., Ghoshal, U., Chandnani, S., Goenka, M. K., & Mitra, M. (2026). Probiotic Blend of Lactobacillus acidophilus LA‐5 and Bifidobacterium animalis ssp. Lactis BB‐12 in Non‐constipated Irritable Bowel Syndrome: A Double‐Blind Randomized Placebo‐Controlled Trial. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70137
Vancouver
Ghoshal UC, Ramakrishna BS, Rathi PM, Shukla A, Panigrahi MK, Jain S, et al. Probiotic Blend of Lactobacillus acidophilus LA‐5 and Bifidobacterium animalis ssp. Lactis BB‐12 in Non‐constipated Irritable Bowel Syndrome: A Double‐Blind Randomized Placebo‐Controlled Trial. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70137
BibTeX
@article{Ghoshal2026,
author = {Ghoshal, Uday C and Ramakrishna, B S and Rathi, Pravin M and Shukla, Akash and Panigrahi, Manas Kumar and Jain, Shubham and Saha, Indraneel and Chakravartty, Karmabir and Singh, Madhuri and Mustafa, Uzma and Sahu, Shikha and Ghoshal, Ujjala and Chandnani, Sanjay and Goenka, Mahesh K and Mitra, Monjori},
title = {Probiotic Blend of Lactobacillus acidophilus LA‐5 and Bifidobacterium animalis ssp. Lactis BB‐12 in Non‐constipated Irritable Bowel Syndrome: A Double‐Blind Randomized Placebo‐Controlled Trial},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
doi = {10.1111/jgh.70137}
}
EUVIMED